Akums Drugs

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE09XN01023
  • NSEID: AKUMS
  • BSEID: 544222
INR
696.05
-16.3 (-2.29%)
BSENSE

Nov 20

BSE+NSE Vol: 1.59 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 10039335,
    "name": "Akums Drugs",
    "stock_name": "Akums Drugs",
    "full_name": "Akums Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/akums-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "696.05",
    "chg": -16.3,
    "chgp": "-2.29%",
    "dir": -1,
    "prev_price": "712.35",
    "mcapval": "11,226.00 Cr",
    "mcap": "Small Cap",
    "scripcode": "544222",
    "symbol": "AKUMS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE09XN01023",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.59 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/akums-drugs-10039335-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Buy",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-buy-4262421",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AkumsDrugsPharm_mojoScore_4262421.png",
        "date": "2026-11-15 10:10:29",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 3 November 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 November 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Gains 0.17%: 5 Key Factors Driving the Week",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/akums-drugs-pharmaceuticals-gains-017-5-key-factors-driving-the-week-4254909",
        "imagepath": "",
        "date": "2026-11-07 10:03:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Nov:</strong> Stock opens at Rs.731.50, marginally down -0.05%</p>\n                    <p><strong>3 Nov:</strong> Strong gap up and upper circuit hit at Rs.806.45</p>\n                    <p><strong>4 Nov:</strong> Quality grade upgraded to good; Mojo Grade upgraded to Buy</p>\n                    <p><strong>5 Nov:</strong> Price consolidates amid mixed volume</p>\n                    <p><strong>6 Nov:</strong> Week closes at Rs.733.15, +0.17% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.731.50</div></div>\n                    <div class=\"s..."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd Upgraded to Buy on Strong Financial and Quality Metrics",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-upgraded-to-buy-on-strong-financial-and-quality-metrics-4250163",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AkumsDrugsPharm_mojoScore_4250163.png",
        "date": "2026-11-04 08:42:55",
        "description": "Akums Drugs & Pharmaceuticals Ltd has seen its investment rating upgraded from Hold to Buy following a comprehensive reassessment of its financial performance, valuation metrics, quality indicators, and technical outlook. The upgrade reflects the company’s robust quarterly results, improved profitability ratios, fair valuation compared to peers, and positive market momentum, signalling renewed investor confidence in this small-cap pharmaceutical player."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd: Valuation Shift Enhances Price Attractiveness Amid Strong Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/akums-drugs-pharmaceuticals-ltd-valuation-shift-enhances-price-attractiveness-amid-strong-returns-4249817",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AkumsDrugsPharm_valuationdot_4249817.png",
        "date": "2026-11-04 08:01:53",
        "description": "Akums Drugs & Pharmaceuticals Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with strong operational metrics and a robust share price performance, has enhanced the stock’s price attractiveness for investors within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd Upgrades Quality Grade Amid Strong Financial Metrics",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/akums-drugs-pharmaceuticals-ltd-upgrades-quality-grade-amid-strong-financial-metrics-4249628",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/AkumsDrugsPharm_qualitydot_4249628.png",
        "date": "2026-11-04 08:00:13",
        "description": "Akums Drugs & Pharmaceuticals Ltd has seen a notable upgrade in its quality grade from average to good, reflecting significant improvements in its business fundamentals. With a current Mojo Score of 74.0 and an upgraded Mojo Grade to Buy from Hold as of 3 Nov 2026, the company’s financial health and operational efficiency have strengthened, positioning it favourably within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Hold",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-hold-4244620",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AkumsDrugsPharm_mojoScore_4244620.png",
        "date": "2026-10-30 10:10:24",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 October 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Hold",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-hold-4230196",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AkumsDrugsPharm_mojoScore_4230196.png",
        "date": "2026-10-19 10:10:22",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO. This rating was last updated on 13 August 2026, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 19 October 2026, providing investors with the most recent data to inform their decisions."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd Sees Technical Momentum Shift Amid Mixed Market Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/akums-drugs-pharmaceuticals-ltd-sees-technical-momentum-shift-amid-mixed-market-signals-4222261",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AkumsDrugsPharm_technicaldot_4222261.png",
        "date": "2026-10-12 08:03:55",
        "description": "Akums Drugs & Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance as of October 2026. Despite a recent 4.44% decline in its share price, the stock continues to demonstrate resilience with mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a nuanced outlook for investors in the pharmaceuticals and biotechnology sector."
      },
      {
        "title": "Akums Drugs & Pharmaceuticals Ltd is Rated Hold",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/akums-drugs-pharmaceuticals-ltd-is-rated-hold-4218679",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/AkumsDrugsPharm_mojoScore_4218679.png",
        "date": "2026-10-08 10:11:08",
        "description": "Akums Drugs & Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      }
    ],
    "total": 71,
    "sid": "10039335",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/akums-drugs-pharmaceuticals-10039335"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "10-Nov-2026",
      "details": "Intimation of Schedule of the Investors/Analysts Meet",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "05-Nov-2026",
      "details": "Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "03-Nov-2026",
      "details": "Audio recording of Earning/ Quarterly Conference Call",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Akums Drugs & Pharmaceuticals Ltd has declared <strong>50%</strong> dividend, ex-date: 03 Jul 26",
          "dt": "2026-07-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

10-Nov-2026 | Source : BSE

Intimation of Schedule of the Investors/Analysts Meet

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

05-Nov-2026 | Source : BSE

Transcript of the Earning/Quarterly Conference Call on the unaudited financial results for the quarter and half year ended on September 30 2026

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

03-Nov-2026 | Source : BSE

Audio recording of Earning/ Quarterly Conference Call

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Akums Drugs & Pharmaceuticals Ltd has declared 50% dividend, ex-date: 03 Jul 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available